These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6341772)

  • 1. Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action.
    Chesnut CH; Ivey JL; Gruber HE; Matthews M; Nelp WB; Sisom K; Baylink DJ
    Metabolism; 1983 Jun; 32(6):571-80. PubMed ID: 6341772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of skeletal calcium deficiency in postmenopausal osteoporosis.
    Burnell JM; Baylink DJ; Chesnut CH; Teubner EJ
    Calcif Tissue Int; 1986 Apr; 38(4):187-92. PubMed ID: 3085896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass.
    Chesnut CH; Nelp WB; Baylink DJ; Denney JD
    Metabolism; 1977 Mar; 26(3):267-77. PubMed ID: 319322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stanozolol stimulates remodelling of trabecular bone and net formation of bone at the endocortical surface.
    Benéton MN; Yates AJ; Rogers S; McCloskey EV; Kanis JA
    Clin Sci (Lond); 1991 Oct; 81(4):543-9. PubMed ID: 1657503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of calcium and stanozolol on calcitonin secretion in patients with femoral neck fracture.
    Beringer TR; Ardill J; Taggart HM
    Bone Miner; 1986 Sep; 1(4):289-95. PubMed ID: 3333017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between local and total bone mass in osteoporosis.
    Manzke E; Chesnut CH; Wergedal JE; Baylink DJ; Nelp WB
    Metabolism; 1975 May; 24(5):605-15. PubMed ID: 1128230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcitriol treatment is not effective in postmenopausal osteoporosis.
    Ott SM; Chesnut CH
    Ann Intern Med; 1989 Feb; 110(4):267-74. PubMed ID: 2913914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis.
    Taggart HM; Applebaum-Bowden D; Haffner S; Warnick GR; Cheung MC; Albers JJ; Chestnut CH; Hazzard WR
    Metabolism; 1982 Nov; 31(11):1147-52. PubMed ID: 6813637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal mass in postmenopausal women.
    Aloia JF; Cohn SH; Ross P; Vaswani A; Abesamis C; Ellis K; Zanzi I
    Am J Physiol; 1978 Jul; 235(1):E82-7. PubMed ID: 677313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver enzymes and lipid levels in patients with lipodermatosclerosis and venous ulcers treated with a prototypic anabolic steroid (stanozolol): a prospective, randomized, double-blinded, placebo-controlled trial.
    Carson P; Hong CJ; Otero-Vinas M; Arsenault EF; Falanga V
    Int J Low Extrem Wounds; 2015 Mar; 14(1):11-8. PubMed ID: 25652757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placebo therapy for postmenopausal osteoporosis.
    Elias C; Heaney RP; Recker RR
    Calcif Tissue Int; 1985 Jan; 37(1):6-13. PubMed ID: 3922599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term calcitonin therapy in postmenopausal osteoporosis.
    Gruber HE; Ivey JL; Baylink DJ; Matthews M; Nelp WB; Sisom K; Chesnut CH
    Metabolism; 1984 Apr; 33(4):295-303. PubMed ID: 6423929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basal plasma immunoreactive calcitonin in postmenopausal osteoporosis.
    Chesnut CH; Baylink DJ; Sisom K; Nelp WB; Roos BA
    Metabolism; 1980 Jun; 29(6):559-62. PubMed ID: 7382823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.
    Chesnut CH; Majumdar S; Newitt DC; Shields A; Van Pelt J; Laschansky E; Azria M; Kriegman A; Olson M; Eriksen EF; Mindeholm L
    J Bone Miner Res; 2005 Sep; 20(9):1548-61. PubMed ID: 16059627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of stanozolol on bone mineral density and bone biomechanical properties of osteoporotic rats.
    Liao JM; Wu T; Li QN; Hu B; Huang LF; Li ZH; Yuan L; Zhong SZ
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1117-20. PubMed ID: 14625163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study.
    Ebeling PR; Wark JD; Yeung S; Poon C; Salehi N; Nicholson GC; Kotowicz MA
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4098-103. PubMed ID: 11549632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.
    Kurland ES; Cosman F; McMahon DJ; Rosen CJ; Lindsay R; Bilezikian JP
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3069-76. PubMed ID: 10999788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis].
    Gennari C; Agnusdei D; Gonnelli S
    Minerva Endocrinol; 1989; 14(1):69-74. PubMed ID: 2659955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum osteocalcin and total body calcium in normal pre- and postmenopausal women and postmenopausal osteoporotic patients.
    Yasumura S; Aloia JF; Gundberg CM; Yeh J; Vaswani AN; Yuen K; Lo Monte AF; Ellis KJ; Cohn SH
    J Clin Endocrinol Metab; 1987 Apr; 64(4):681-5. PubMed ID: 3493257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total body calcium by neutron activation analysis in normals and osteoporotic populations: a discriminator of significant bone mass loss.
    Ott SM; Murano R; Lewellen TK; Nelp WB; Chesnut CM
    J Lab Clin Med; 1983 Oct; 102(4):637-45. PubMed ID: 6619649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.